{"title":"全氟丁烷改良超声造影LI-RADS在高危肝细胞癌患者中的应用：系统综述和网络荟萃分析","authors":"Jifan Chen, Jianing Zhu, Jiaxing Shen, Yuhan Fu, Fei Gao, Jing Wang, Peile Jin, Tao Lin, Yang Sun, Qiu Chen, Ying Zhang, Guowei Wang, Chao Zhang, Jianhua Zhou, Xiang Jing, Pintong Huang","doi":"10.1016/j.ultrasmedbio.2025.05.024","DOIUrl":null,"url":null,"abstract":"<p><p>Contrast-enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) 2017 version is based on pure-blood pool contrast agent, potentially unsuitable for perfluorobutane contrast agent with the Kupffer phase. This article aimed to compare the diagnostic performance of unmodified CEUS LI-RADS and modified CEUS LI-RADS using perfluorobutane for hepatocellular carcinoma by integrating published and original data from three medical centers. Comparison between unmodified and modified CEUS LI-RADS with perfluorobutane involved ranking the diagnostic odds ratio (DOR) and superiority index (SI) using an ANOVA arm-based model. This meta-analysis included nine studies and our original data, encompassing 1505 patients with 1622 lesions. The summarized sensitivity of the modified CEUS LI-RADS was higher than that of the unmodified version (0.77 [0.72-0.81] vs. 0.70 [0.63-0.76]), while specificity was similar for both (0.86 [0.78-0.91] vs. 0.86 [0.77-0.92]). The general diagnostic performance of the modified CEUS LI-RADS was superior to the unmodified version, indicated by a higher DOR (16.98 [11.65-23.43] vs. 12.51 [8.11-18.44], p = 0.02) and SI (1.59 [1.00-3.00] vs. 0.80 [0.33-1.00], p = 0.02). Modified CEUS LI-RADS may be of better diagnostic performance, offering higher sensitivity without compromising specificity.</p>","PeriodicalId":49399,"journal":{"name":"Ultrasound in Medicine and Biology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Modified CEUS LI-RADS With Perfluorobutane in Patients at High-Risk for Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis.\",\"authors\":\"Jifan Chen, Jianing Zhu, Jiaxing Shen, Yuhan Fu, Fei Gao, Jing Wang, Peile Jin, Tao Lin, Yang Sun, Qiu Chen, Ying Zhang, Guowei Wang, Chao Zhang, Jianhua Zhou, Xiang Jing, Pintong Huang\",\"doi\":\"10.1016/j.ultrasmedbio.2025.05.024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Contrast-enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) 2017 version is based on pure-blood pool contrast agent, potentially unsuitable for perfluorobutane contrast agent with the Kupffer phase. This article aimed to compare the diagnostic performance of unmodified CEUS LI-RADS and modified CEUS LI-RADS using perfluorobutane for hepatocellular carcinoma by integrating published and original data from three medical centers. Comparison between unmodified and modified CEUS LI-RADS with perfluorobutane involved ranking the diagnostic odds ratio (DOR) and superiority index (SI) using an ANOVA arm-based model. This meta-analysis included nine studies and our original data, encompassing 1505 patients with 1622 lesions. The summarized sensitivity of the modified CEUS LI-RADS was higher than that of the unmodified version (0.77 [0.72-0.81] vs. 0.70 [0.63-0.76]), while specificity was similar for both (0.86 [0.78-0.91] vs. 0.86 [0.77-0.92]). The general diagnostic performance of the modified CEUS LI-RADS was superior to the unmodified version, indicated by a higher DOR (16.98 [11.65-23.43] vs. 12.51 [8.11-18.44], p = 0.02) and SI (1.59 [1.00-3.00] vs. 0.80 [0.33-1.00], p = 0.02). Modified CEUS LI-RADS may be of better diagnostic performance, offering higher sensitivity without compromising specificity.</p>\",\"PeriodicalId\":49399,\"journal\":{\"name\":\"Ultrasound in Medicine and Biology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ultrasound in Medicine and Biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ultrasmedbio.2025.05.024\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ACOUSTICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ultrasound in Medicine and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ultrasmedbio.2025.05.024","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ACOUSTICS","Score":null,"Total":0}
Modified CEUS LI-RADS With Perfluorobutane in Patients at High-Risk for Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis.
Contrast-enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) 2017 version is based on pure-blood pool contrast agent, potentially unsuitable for perfluorobutane contrast agent with the Kupffer phase. This article aimed to compare the diagnostic performance of unmodified CEUS LI-RADS and modified CEUS LI-RADS using perfluorobutane for hepatocellular carcinoma by integrating published and original data from three medical centers. Comparison between unmodified and modified CEUS LI-RADS with perfluorobutane involved ranking the diagnostic odds ratio (DOR) and superiority index (SI) using an ANOVA arm-based model. This meta-analysis included nine studies and our original data, encompassing 1505 patients with 1622 lesions. The summarized sensitivity of the modified CEUS LI-RADS was higher than that of the unmodified version (0.77 [0.72-0.81] vs. 0.70 [0.63-0.76]), while specificity was similar for both (0.86 [0.78-0.91] vs. 0.86 [0.77-0.92]). The general diagnostic performance of the modified CEUS LI-RADS was superior to the unmodified version, indicated by a higher DOR (16.98 [11.65-23.43] vs. 12.51 [8.11-18.44], p = 0.02) and SI (1.59 [1.00-3.00] vs. 0.80 [0.33-1.00], p = 0.02). Modified CEUS LI-RADS may be of better diagnostic performance, offering higher sensitivity without compromising specificity.
期刊介绍：
Ultrasound in Medicine and Biology is the official journal of the World Federation for Ultrasound in Medicine and Biology. The journal publishes original contributions that demonstrate a novel application of an existing ultrasound technology in clinical diagnostic, interventional and therapeutic applications, new and improved clinical techniques, the physics, engineering and technology of ultrasound in medicine and biology, and the interactions between ultrasound and biological systems, including bioeffects. Papers that simply utilize standard diagnostic ultrasound as a measuring tool will be considered out of scope. Extended critical reviews of subjects of contemporary interest in the field are also published, in addition to occasional editorial articles, clinical and technical notes, book reviews, letters to the editor and a calendar of forthcoming meetings. It is the aim of the journal fully to meet the information and publication requirements of the clinicians, scientists, engineers and other professionals who constitute the biomedical ultrasonic community.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
